Navigation Links
Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy
Date:3/20/2009

herapy related weight loss."

"These results are of special interest in light of ensuring an even more effective supportive care to patients undergoing high emetogenic chemotherapy. From this point of view, such an outcome is consistent with Helsinn's commitment in this particular setting," stated Prof. Mauro Bianchi, Medical Development Director at Helsinn.

About Chemotherapy-induced nausea and vomiting (CINV)

Chemotherapy-induced nausea and vomiting is among the most dreaded side effects following therapy in patients with cancer. Despite prophylaxis, on the day of chemotherapy, up to 30-45 percent of patients experience nausea or vomiting or require rescue therapy following administration of certain types of emetogenic chemotherapy. The 5-HT3 receptor plays a pivotal role in the process of emesis, and agents that antagonise these receptor subtypes are the basis for control of this effect. Following the development of the first generation 5-HT3 receptor antagonists, such as ondansetron and granisetron, in the late '80s and early '90s, in recent years new compounds have been made available for preventing CINV, including palonosetron.

About Palonosetron (Aloxi(R), Onicit(R), Paloxi(R))

Palonosetron (palonosetron hydrochloride) is a selective 5-HT3 receptor antagonist, developed for the prevention of CINV in patients with cancer, with a long half-life of 40 hours and at least 30 times higher receptor binding affinity than currently available compounds. Palonosetron is a second generation 5-HT3 receptor antagonist, and demonstrates, in clinical trials and clinical practice, a unique long-lasting action in the prevention of CINV. Since its availability in USA in September 2003, and since then in more than 40 countries world-wide, there have been over 10 million administrations of palonosetron. The product has shown to be effective in preventing both acute and delayed CINV in patie
'/>"/>

SOURCE Helsinn Healthcare SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
2. Imagenetix Reports Results of Offer to Extend Warrants
3. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
4. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
7. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
8. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
9. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
10. Results of Study in Pre-School Children Published in Clinical Pediatrics Adds to Support for Importance of Dietary DHA Intake
11. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... and CINCINNATI , March ... (LSE: SHP, NASDAQ: SHPG ) and Cincinnati ... broad research collaboration for rare diseases. The goal of ... therapies to treat rare diseases with high unmet ... with Cincinnati Children,s research expertise. As a nationally ...
(Date:3/26/2015)... 26, 2015 Ale Gicqueau, Founder and ... of Clinical Affairs at Align Technology, on “ Conducting ... upcoming ACRP 2015 Global Conference and Exhibition on April ... , During the poster presentation, Ale Gicqueau and ... running a Postmarket Registry, the requirements and resources to ...
(Date:3/25/2015)... 2015 Optimal Research, LLC has been nominated ... Award "Best Clinical Site or Trial Network". ... been selected as a nominee in this ViE award ... Recommended" distinction in 2014. The ViE awards were created ... and positive contributions of companies and individuals in the ...
(Date:3/25/2015)... and REYKJAVIK, Iceland , March 25, ... using the genome to create better medicine, today congratulated the ... studies of whole-genome data yet undertaken. The ... – are built around the most comprehensive population-wide ... of deCODE scientists led by Kari Stefansson , deCODE,s ...
Breaking Biology Technology:Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2
... CALGARY, May 14 /PRNewswire-FirstCall/ - Oncolytics Biotech ... it has,received a letter of approval from ... (MHRA) for its Clinical Trial Application (CTA),to ... intravenous administration of,REOLYSIN(R) in combination with paclitaxel ...
... Sky One,Medical, Inc. (OTC Bulletin Board: CSKI; "China ... and distributor of pharmaceutical,medicinal and diagnostic products, announced ... made in conjunction with the Company,filing an application ... Exchange., As of May 7, 2008, Mr. ...
... 13 PharmAthene, Inc.,(Amex: PIP ) a ... threats, today reported financial results for the,first quarter ... was a particularly productive and exciting time for,our ... completed on April 2, 2008, PharmAthene made substantial,progress ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2China Sky One Medical, Inc. Changes Management Team 2China Sky One Medical, Inc. Changes Management Team 3PharmAthene Reports First Quarter 2008 Financial Results 2PharmAthene Reports First Quarter 2008 Financial Results 3PharmAthene Reports First Quarter 2008 Financial Results 4PharmAthene Reports First Quarter 2008 Financial Results 5PharmAthene Reports First Quarter 2008 Financial Results 6PharmAthene Reports First Quarter 2008 Financial Results 7
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... OXFORD, Conn. , Mar. 23, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, announces ... a new advertising campaign on CNBC television starting March 30 ... ads will commence airing in New York ... Executive Officer said: "We are excited about our new ad ...
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... July 6 Delays in cargo screening significantly extend ... be shortened with foolproof and rapid screening and detection ... smuggling augment the need for efficient access control systems ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , New analysis from ...
... , WASHINGTON, July 7 Eight supply chain professionals were ... organization,s Board of Directors, joining the seven existing members of SCC,s board. ... through June 30, 2012, are as follows: , , , ... CTO, Manufacturing & Distribution Industries, Hewlett Packard , ...
... , , LONDON, July 10 IBM (NYSE: ... executive agency of the UK Home Office, have signed a seven-year agreement ... upgrade to biometric passports and enhance the security of the UK border. ... (UKBA) Immigration and Asylum Fingerprint System (IAFS) which holds biometrics collected from ...
Cached Biology News:Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan 2Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan 3UK Identity and Passport Service and IBM Sign 7-year National Biometric Identity Service (NBIS) Contract 2
This kit is designed to select cells labeled with phycoerythrin- (PE-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... easy to supply microplates, deepwells, and tips ... convenience in mind, iLink incorporates multiple functions ... The iLink software is the key to ... that can be copied and installed as ...
... Caliper software products bring you ease of use and rapid solutions to meet your laboratory's requirements ... ... ... CLARA® is the standard software for ...
... As research demands continue to grow, ... more spectral information has become necessary, especially ... spectral colors. The innovative C1si Confocal Microscope ... speed and spectral capability not available in ...
Biology Products: